EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,847,861 | +4.4% | 450,703 | -8.7% | 0.06% | +10.3% |
| Q2 2023 | $9,429,084 | -3.1% | 493,411 | -1.6% | 0.06% | -9.4% |
| Q1 2023 | $9,731,242 | +20.5% | 501,352 | -0.5% | 0.06% | +14.3% |
| Q4 2022 | $8,078,979 | +1.2% | 503,677 | -1.1% | 0.06% | -3.4% |
| Q3 2022 | $7,985,000 | -27.8% | 509,226 | -4.2% | 0.06% | -22.7% |
| Q2 2022 | $11,061,000 | -9.3% | 531,285 | -1.3% | 0.08% | +11.9% |
| Q1 2022 | $12,200,000 | +24.2% | 538,176 | +0.2% | 0.07% | +36.7% |
| Q4 2021 | $9,820,000 | -14.7% | 537,176 | -1.4% | 0.05% | -19.7% |
| Q3 2021 | $11,517,000 | +13.1% | 544,777 | -2.5% | 0.06% | +79.4% |
| Q2 2021 | $10,184,000 | -20.4% | 558,957 | -1.3% | 0.03% | -24.4% |
| Q1 2021 | $12,798,000 | +13.6% | 566,512 | +1.0% | 0.04% | +7.1% |
| Q4 2020 | $11,262,000 | -18.9% | 561,129 | -1.2% | 0.04% | -37.3% |
| Q3 2020 | $13,881,000 | +1.8% | 567,745 | -1.2% | 0.07% | +1.5% |
| Q2 2020 | $13,639,000 | +33.5% | 574,496 | -3.2% | 0.07% | +17.9% |
| Q1 2020 | $10,215,000 | -1.3% | 593,234 | +1.0% | 0.06% | +40.0% |
| Q4 2019 | $10,348,000 | +0.5% | 587,265 | +0.9% | 0.04% | -4.8% |
| Q3 2019 | $10,293,000 | -18.4% | 582,013 | -1.4% | 0.04% | -14.3% |
| Q2 2019 | $12,620,000 | -11.7% | 590,538 | -1.6% | 0.05% | -9.3% |
| Q1 2019 | $14,285,000 | +18.8% | 600,227 | -1.8% | 0.05% | +10.2% |
| Q4 2018 | $12,020,000 | +11.7% | 611,085 | +0.6% | 0.05% | +36.1% |
| Q3 2018 | $10,765,000 | +6935.9% | 607,533 | +8466.5% | 0.04% | +3500.0% |
| Q2 2018 | $153,000 | +3.4% | 7,092 | +6.4% | 0.00% | 0.0% |
| Q1 2018 | $148,000 | -28.8% | 6,667 | -2.6% | 0.00% | 0.0% |
| Q4 2017 | $208,000 | +20.2% | 6,844 | -2.3% | 0.00% | 0.0% |
| Q2 2017 | $173,000 | -94.2% | 7,006 | -94.9% | 0.00% | -90.9% |
| Q1 2017 | $2,984,000 | +53.0% | 137,684 | +5.3% | 0.01% | +37.5% |
| Q4 2016 | $1,950,000 | -99.9% | 130,760 | -0.3% | 0.01% | +14.3% |
| Q3 2016 | $1,676,718,000 | +64.0% | 131,096 | +0.2% | 0.01% | +75.0% |
| Q2 2016 | $1,022,290,000 | +76.6% | 130,895 | -9.5% | 0.00% | +100.0% |
| Q1 2016 | $579,000,000 | -19.8% | 144,660 | +13.0% | 0.00% | -33.3% |
| Q4 2015 | $722,000,000 | +100879.0% | 128,013 | +0.4% | 0.00% | 0.0% |
| Q3 2015 | $715,000 | -99.8% | 127,552 | +6.8% | 0.00% | +50.0% |
| Q2 2015 | $449,000,000 | +36.8% | 119,415 | -6.5% | 0.00% | +100.0% |
| Q1 2015 | $328,220,000 | +78.5% | 127,712 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $183,906,000 | -9.3% | 127,712 | -3.7% | 0.00% | 0.0% |
| Q3 2014 | $202,809,000 | -54.7% | 132,555 | +0.4% | 0.00% | -50.0% |
| Q2 2014 | $447,677,000 | -2.7% | 132,058 | +1.6% | 0.00% | 0.0% |
| Q1 2014 | $460,165,000 | -38.5% | 129,990 | +6.4% | 0.00% | -50.0% |
| Q4 2013 | $748,590,000 | +4.3% | 122,119 | -1.0% | 0.00% | 0.0% |
| Q3 2013 | $717,862,000 | +22.9% | 123,344 | -4.1% | 0.00% | +33.3% |
| Q2 2013 | $583,990,000 | – | 128,632 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |